ÄϹ¬ng28ÏàÐÅÆ·ÅÆÁ¦Á¿

EN
ÐÂÎÅÖÐÐÄ

»Ý¼°¸ü¶à»¼Õߣ¡Êæ¿ì´ï?·Çŵ±´ÌØËᵨ¼î»ºÊͽºÄÒÄÉÈë¹ú¶ÈÒ½±£Ä¿Â¼

 

°ä²¼¹¦·ò : 2024-11-29

ÄϹ¬NG¡¤28(ÖйúÇø)ÏàÐÅÆ·ÅÆÁ¦Á¿ÓÐÏÞ¹«Ë¾

 

11ÔÂ28ÈÕ£¬¹ú¶ÈÒ½ÁƱ£ÏÕ¾Ö¡¢ÈËÁ¦×ÊÔ´ºÍÉç»á±£ÏÕ²¿Õýʽ°ä²¼ÁË¡¶¹ú¶È¸ù»ùÒ½ÁƱ£ÏÕ¡¢¹¤É˱£ÏÕºÍÉúÓý±£ÏÕҩƷĿ¼(2024Äê)¡·¡£Êæ¿ì´ï®·Çŵ±´ÌØËᵨ¼î»ºÊͽºÄÒ¾­½»Éæ³õ´Î±»ÄÉÈë¹ú¶ÈÒ½±£Ä¿Â¼¡£Ð°æÄ¿Â¼½«ÓÚ2025Äê1ÔÂ1ÈÕÕýʽִÐС£

×¢Ã÷: E:\»ôÇÉÕä\3.ÆóÒµÐû´«\3.¿¯Îï\ÄÚ¿¯\ÄÚ¿¯Îļþ\2024Äê\12Ô¿¯\10.·Çŵ±´ÌؽøÈëÒ½±£\΢ÐŽØÍ¼_20241128114133.png

 

Êæ¿ì´ï®·Çŵ±´ÌØËᵨ¼î»ºÊͽºÄÒ

       ·Çŵ±´ÌØËᵨ¼î»ºÊͽºÄÒÊô±´ÌØÀàѪ֬µ÷½ÚÒ©£¬Í¨¹ýÒÖÔ켫µÍÃܶÈÖ¬µ°°×µ¨¹Ì´¼ºÍ¸ÊÓÍÈýõ¥µÄÌìÉú²¢Í¬Ê±Ê¹Æä·Ö»¯´úлÔö¶à£¬½µµÍѪµÍÃܶÈÖ¬µ°°×µ¨¹Ì´¼ºÍ¸ÊÓÍÈýõ¥£»»¹Ê¹ÔØÖ¬µ°°×A1ºÍA11ÌìÉúÔö³¤£¬´Ó¶øÔö¸ß¸ßÃܶÈÖ¬µ°°×µ¨¹Ì´¼¡£Êæ¿ì´ï®·Çŵ±´ÌØËᵨ¼î»ºÊͽºÄÒÓÅ»¯µ¨¼îÑνṹ£¬ÓµÓнϺõÄË®ÈÜÐÔ£¬ÏÔÖøÌáÉýÁËÉúÎïÀûÓöÈ[1]£»Ò»´ÎÒ»Á££¨135mg£©,Ò»ÌìÒ»´Î£¬ÎÞÐèÓë²Íͬ·þ£¬ÌáÉýÓÃÒ©·½±ãÐÔ[2]¡ £¿ÉÖ±½ÓÔÚÌåÄÚ²ûÑï×÷Óã¬ÎÞÐè¾­¹ý¸ÎÔàÊ×¹ý´úл£¬´Ó¶ø¿É½µµÍ¸ÎÔàÖ°ÊØ[1]¡£ËµÃ÷ÊéÖ¸³ö£¬±¾Æ·ÓëËûÍ¡ÀàÒ©Îï½áºÏʹÓÃÎÞÐèµ÷Õû±¾Æ·»òºÏÓÃÒ©ÎïµÄ¼ÁÁ¿¡£

 

ºÏ×÷Õ÷ѯÈÈÏß:4001833668

¿ÉɨÂëµÇ¼ÇºÏ×÷ÐÅÏ¢

ÄϹ¬NG¡¤28(ÖйúÇø)ÏàÐÅÆ·ÅÆÁ¦Á¿ÓÐÏÞ¹«Ë¾

²Î¿¼×ÊÁÏ£º

[1]     Elisavet Moutzouri ,Anastazia Kei,Moses S elisaf ,Haralampos J Milionis.Management of dyslipidemias with fibrates, alone and in combination with statins: role of delayed-release fenofibric acid.Vascular Health and Risk Management 2010:6 525–539.

[2]   ·Çŵ±´ÌØËᵨ¼î»ºÊͽºÄÒ˵Ã÷Êé.

ÓйØÐÂÎÅ

2026-02-03

²¼¸æ | ÄϹ¬ng28ÏàÐÅÆ·ÅÆÁ¦Á¿°¢ÂØì¢ËáÄÆ¿Ú·þÈÜÒº»ñÅúÉÏÊÐ

2026-01-08

²¼¸æ | ÄϹ¬ng28ÏàÐÅÆ·ÅÆÁ¦Á¿Á×Ëá°Â˾ËûΤ½ºÄÒйæ¸ñ»ñÅúÉÏÊÐ

2025-12-29

ÄϹ¬ng28ÏàÐÅÆ·ÅÆÁ¦Á¿²Î¹ÉÈ«Çòµ±ÏȵķÖ×Ó½ºÀàÐÂÐ͵°°×½µ½â¼ÁÑз¢¹«Ë¾´ï¸èÉúÎïDegron Therapeutics

Ïàʶ¸ü¶à
¡¾ÍøÕ¾µØÍ¼¡¿